Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors
摘要:
We have made a novel series of pyrazolo[1,5-a]pyridines as PI3 kinase inhibitors, and demonstrated their selectivity for the p110 alpha isoform over the other Class Ia PI3 kinases. We investigated the SAR around the pyrazolo[1,5-a] pyridine ring system, and found compound 5x to be a particularly potent example (p110 alpha IC50 0.9 nM). This compound inhibits cell proliferation and phosphorylation of Akt/PKB, a downstream marker of PI3 kinase activity, and showed in vivo activity in an HCT-116 human xenograft model. (C) 2011 Elsevier Ltd. All rights reserved.
Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors
摘要:
We have made a novel series of pyrazolo[1,5-a]pyridines as PI3 kinase inhibitors, and demonstrated their selectivity for the p110 alpha isoform over the other Class Ia PI3 kinases. We investigated the SAR around the pyrazolo[1,5-a] pyridine ring system, and found compound 5x to be a particularly potent example (p110 alpha IC50 0.9 nM). This compound inhibits cell proliferation and phosphorylation of Akt/PKB, a downstream marker of PI3 kinase activity, and showed in vivo activity in an HCT-116 human xenograft model. (C) 2011 Elsevier Ltd. All rights reserved.
[EN] TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR<br/>[FR] COMPOSÉS DE TRIAZOLE FURANE UTILISÉS EN TANT QU'AGONISTES DU RÉCEPTEUR APJ
申请人:AMGEN INC
公开号:WO2018097944A1
公开(公告)日:2018-05-31
Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed.
Enantioselective Hydrogenation of Imidazo[1,2-<i>a</i>
]pyridines
作者:Christoph Schlepphorst、Mario P. Wiesenfeldt、Frank Glorius
DOI:10.1002/chem.201705370
日期:2018.1.9
of tetrahydroimidazo[1,2‐a]pyridines by direct hydrogenation was achieved using a ruthenium/N‐heterocyclic carbene (NHC) catalyst. The reaction forgoes the need for protecting or activating groups, proceeds with complete regioselectivity, good to excellent yields, enantiomeric ratios of up to 98:2, and tolerates a broad range of functional groups. 5,6,7,8‐Tetrahydroimidazo[1,2‐a]pyridines, which are
使用钌/ N-杂环卡宾(NHC)催化剂,通过直接氢化完成对四氢咪唑并[1,2- a ]吡啶的对映选择性合成。该反应放弃了对保护基团或活化基团的需要,以完全的区域选择性,良好至优异的产率,高达98:2的对映体比例进行,并且耐受宽泛的官能团。5,6,7,8-四氢咪唑并[1,2一]吡啶,其在许多生物活性分子中发现,直接通过该方法获得的,其适用性是由几个功能性分子的(正式)合成证明。
HPK1 ANTAGONISTS AND USES THEREOF
申请人:Nimbus Saturn, Inc.
公开号:US20210078996A1
公开(公告)日:2021-03-18
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
本发明提供了化合物、其组合物以及使用这些化合物用于抑制HPK1和治疗HPK1介导的疾病的方法。
PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS
申请人:Gilead Sciences, Inc.
公开号:US20130164280A1
公开(公告)日:2013-06-27
The invention provides compounds and pharmaceutically acceptable salts and esters and compositions thereof, for treating viral infections. The compounds and compositions are useful for treating Pneumovirinae virus infection including Human respiratory syncytial virus infections.
[EN] SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES<br/>[FR] AMINES BICYCLIQUES SUBSTITUÉES POUR LE TRAITEMENT DU DIABÈTE
申请人:MERCK SHARP & DOHME
公开号:WO2010056717A1
公开(公告)日:2010-05-20
Described herein are substituted bicyclic amines. In particular, described herein are substituted bicyclic amines that are effective as antagonists of SSTR5 and useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, metabolic syndrome, depression, and anxiety.